STCube Confirms Expression Rate of New Drug Candidate 'STT-003'... "Significantly Superior to Existing Immuno-Oncology Drugs"

[Asia Economy Reporter Hyunseok Yoo] STCube, a bio company developing immune checkpoint inhibitors, announced on the 3rd that it has begun selecting patient groups for its new drug candidate antibody STT-003.

A company official stated, “We have entered the full preclinical stage starting with the results of tumor tissue staining for the new drug candidate STT-003, which overcomes the limitations of existing immune checkpoint inhibitors. The tumor tissue immunohistochemistry test confirmed that the expression rate is higher than that of PD-1/PD-L1 antibodies, which are the backbone of existing immune checkpoint inhibitors.”

STCube is discovering immune checkpoint inhibitor candidates capable of anticancer drug development within its proprietary gene pool using its self-developed screening technology. It is conducting anticancer research on candidate substances jointly discovered with the MD Anderson Cancer Center, the world’s leading cancer research institution in the United States.

The STT-003 antibody is a new drug candidate substance that has previously signed a Material Transfer Agreement (MTA) with multinational pharmaceutical companies and conducted joint research. The efficacy of combination therapy administering PD-1/PD-L1 antibodies and the STT-003 antibody simultaneously has already been confirmed.

Immunohistochemistry was performed on tumor tissues from lung cancer, head and neck cancer, esophageal cancer, and bladder cancer, confirming that the expression rate of STT-003 is significantly higher than that of PD-L1. STT-003 expression in normal tissues is extremely limited, so side effects from drug treatment are expected to be minimal. A company official said, “Based on preclinical results, Phase 1 clinical trials of STT-003 will be conducted as monotherapy. We plan to collaborate with MD Anderson Cancer Center and leading university hospitals in the United States to carry out clinical trials.”

This content was produced with the assistance of AI translation services.